Citius Oncology grants director Holuka 125K options

Q: What are the terms of Eugene Myron Holuka's new CTOR options?

Director Eugene Myron Holuka received 125,000 options with a $0.5223 exercise price. They vest in full on November 12, 2027, subject to continuous service to Citius Oncology or a Related Entity, and expire November 12, 2036.

Q: What other CTOR equity awards are listed for Eugene Myron Holuka?

The report lists 125,000 options at a $1.07 exercise price, vesting one-third on each of the first, second and third anniversaries of their December 12, 2024 grant, and expiring December 12, 2034. It also lists 150,000 fully vested options at $2.15, expiring July 5, 2033, and restricted stock units covering 300,000 shares, subject to their stated service-based vesting condition.

Available on EDGAR 11/13/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:30 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Citius Oncology, Inc. granted director Eugene Myron Holuka 125,000 stock options on November 12, 2026, at a $0.5223 exercise price, expiring November 12, 2036. They vest in full on November 12, 2027, subject to continuous service to the company or a Related Entity. The report also lists 125,000 options at $1.07, expiring December 12, 2034; 150,000 options at $2.15, expiring July 5, 2033; and restricted stock units covering 300,000 shares, vesting in full on the third anniversary of September 19, 2025, subject to continuous service.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Holuka Eugene Myron

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F2	125,000	$0.00	$0.00
Holding	Stock Option (Right to Buy) ^F3	--	--	--
Holding	Stock Option (Right to Buy) ^F4	--	--	--
Holding	Common Stock ^F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 400,000 options, with 275,000 underlying shares of Common Stock (Direct); Common Stock — 300,000 shares (Direct)

Footnotes (4)

F1. Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
F2. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
F3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
F4. These options are 100% vested.

Key Figures

New option award: 125,000 stock options Exercise price: $0.5223 per share New option vesting date: November 12, 2027 +4 more

7 metrics

New option award 125,000 stock options Granted November 12, 2026

Exercise price $0.5223 per share New option award

New option vesting date November 12, 2027 Vests in full, subject to continuous service

New option expiration date November 12, 2036 New option award

Other options 125,000 underlying shares Exercise price $1.07; expiration December 12, 2034

Other options 150,000 underlying shares Exercise price $2.15; expiration July 5, 2033

Restricted stock units 300,000 underlying shares Vesting in full on the third anniversary of September 19, 2025, subject to continuous service

Key Terms

restricted stock units, Continuous Service, Related Entity, vest in full

4 terms

restricted stock units financial

"Represents restricted stock units granted on September 19, 2025"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Continuous Service technical

"subject to the Reporting Person's Continuous Service"

vest in full technical

"The options vest in full on November 12, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Eugene Myron Holuka's new CTOR options?

Director Eugene Myron Holuka received 125,000 options with a $0.5223 exercise price. They vest in full on November 12, 2027, subject to continuous service to Citius Oncology or a Related Entity, and expire November 12, 2036.

What other CTOR equity awards are listed for Eugene Myron Holuka?

The report lists 125,000 options at a $1.07 exercise price, vesting one-third on each of the first, second and third anniversaries of their December 12, 2024 grant, and expiring December 12, 2034. It also lists 150,000 fully vested options at $2.15, expiring July 5, 2033, and restricted stock units covering 300,000 shares, subject to their stated service-based vesting condition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holuka Eugene Myron

(Last)

(First)

(Middle)

C/O CITIUS ONCOLOGY, INC.

11 COMMERCE DRIVE, 1ST FLOOR

(Street)

CRANFORD

NEW JERSEY

07016

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CITIUS ONCOLOGY, INC. [ CTOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								300,000⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.5223	11/12/2026		A		125,000		⁽²⁾	11/12/2036	Common Stock	125,000	$0	125,000	D
Stock Option (Right to Buy)	$1.07							⁽³⁾	12/12/2034	Common Stock	125,000		125,000	D
Stock Option (Right to Buy)	$2.15							⁽⁴⁾	07/05/2033	Common Stock	150,000		150,000	D

Explanation of Responses:

1. Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

2. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

4. These options are 100% vested.

	/s/ Alexander M. Donaldson, by Power of Attorney	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR